• ← Longitudinal Analysis of NDMM
  • / Downloads

    • Clinical Labs & Metadata

    Clinical assessment data

    As patients were enrolled and underwent therapy, clinicians collected information used to assess disease burden and treatment outcomes.

    Here, we provide descriptions from clinical imaging - CT, PETCT, Osseous survey, MRI, and X-ray - as well as bone density scans, that were used to assess disease burden at Pre-Treatment and End of Induction timepoints.

    We also provide assessments of International Myeloma Working Group (IMWG) High-Risk Multiple Myeloma (HRMM) status of each patient at enrollment. Note: HRMM was assessed without TP53 mutation status, and may be an underestimate of high-risk classification.

    Finally we provide the clinically assessed treatment response based on tumor burden results at End of Induction and Post-Transplant time points: Progressive disease, Partial Response (PR), Very Good Partial Response (VGPR), Complete Response (CR), or Stringent Complete Response (sCR).

    For details about the columns in these tables, click the header below:

    Clinical imaging columns

    subject.subjectGuid: A Globally Unique Identifier (GUID) for the Subject
    subject.visitName: Name of the treatment visit
    imaging.performedAtVisit: Whether or not imaging was performed at the treatment visit; Yes or No
    imaging.assayType: Imaging assay performed at visit
    imaging.clinicalNotes: Clinical notes from assessment of imaging assay results
    imaging.boneDisease: Whether bone disease was noted as present based on imaging results
    imaging.additionalComments: Additional comments regarding the imaging assay

    Tumor burden columns

    subject.subjectGuid: A Globally Unique Identifier (GUID) for the subject
    sample.daysSinceFirstVisit: Timing of visit sample as days after the first visit
    subject.treatmentGroup: Induction therapy treatment group; VRd or VRd_Dara
    sample.visitName: Name of the patient visit
    sample.visitDetails: Details of the patient visit
    tb.responseAtVisit: Investigator assessed response category at this visit
    tb.perc_abnormal_flow: % abnormal plasma cells by bone marrow morphology
    tb.perc_abnormal_morph: % abnormal plasma cells by flowcytometry
    tb.was_perc_abnormal_by_ihc: Was % abnormal plasma cells value determined by IHC (CD138+)?

    IMWG HRMM assessment columns

    subject.subjectGuid: A Globally Unique Identifier (GUID) for the subject
    subject.treatmentGroup: Induction therapy treatment group; VRd or VRd_Dara
    subject.biologicalSex: Biological sex of the subject
    sample.visitName: Name of the treatment visit
    chem.albumin: Blood chemistry measurement: Albumin
    chem.creatinine: Blood chemistry measurement: Creatinine
    chem.ldh: Blood chemistry measurement: Lactate Dehydrogenase
    cyto.17p_loss: Cytogenetics: 17p-
    cyto.1q_gain: Cytogenetics: 1p-
    cyto.1p_loss: Cytogenetics: 1q+
    cyto.t11_14: Cytogenetics: t(11:14)
    cyto.t14_16: Cytogenetics: t(14:16)
    cyto.t14_20: Cytogenetics: t(14:20)
    cyto.t4_14: Cytogenetics: t(4:14)
    spe.albumin: Serum Protein Electrophoresis: Albumin
    spe.b2m: Serum Protein Electrophoresis: Beta 2 Microglobulin
    tb.riss_stage: Tumor burden: RISS stage; I, II, or III
    tb.hrmm: Tumor burden: High Risk Multiple Myeloma as assessed by IMWG standards
    tb.hrmmNotes: Notes regarding HRMM assessment

    NDMM Clinical Disease Assessment
    File NameDescriptionDownload Link
    ndmm_clinical_imaging.tsv Clinical imaging assay results
    ndmm_clinical_imaging_desc.tsv Clinical imaging assay result column descriptors
    ndmm_imwg_hrmm_cytogenetics.tsv IMWG HRMM assessment results
    ndmm_imwg_hrmm_cytogenetics_desc.tsv IMWG HRMM assessment result column descriptors
    ndmm_tumor_burden.tsv Tumor burden results
    ndmm_tumor_burden_desc.tsv Tumor burden results column descriptors

    Genotyping data

    As part of patient and disease characterization, each patient was assessed to identify Human Leukocyte Antigen (HLA) genotype, Killer cell Immunoglobulin-like Receptor (KIR) genotype, and Fc Gamma Receptor (FCGR) genotype.

    Click the header below for descriptions of the columns in these genotyping results tables:

    HLA genotyping columns

    subject.subjectGuid: A Globally Unique Identifier (GUID) for the Subject
    sample.sampleKitGuid: A GUID for the Sample Kit, representing all material collected at a visit
    specimen.specimenGuid: A GUID for the specific aliquot used for the experiment
    hla.locus: HLA: Locus assessed
    hla.allele_1: HLA: Locus observed on allele 1
    hla.allele_2: HLA: Locus observed on allele 2
    hla.diploid_ambiguities: HLA: Diploid ambiguities
    hla.allele_1_ambiguities: HLA: Ambiguities observed on allele 1
    hla.allele_2_ambiguities: HLA: Ambiguities observed on allele 2

    KIR genotyping columns

    subject.subjectID: A Globally Unique Identifier (GUID) for the Subject
    sample.sampleKitGuid: A GUID for the Sample Kit, representing all material collected at a visit
    specimen.specimenGuid: A GUID for the specific aliquot used for the experiment
    sample.tissue: Tissue of the sample used for KIR assessment; PBMC or BMMC
    sample.visitName: Name of the patient visit
    sample.daysSinceFirstVisit: Timing of visit sample as days after the first visit
    kir.haplotype: Killer-cell Ig-like Receptor: Haplotype
    kir.ambiguity: Killer-cell Ig-like Receptor: Whether ambiguous results are present; 1, yes; 0, no
    kir.mostCommonHaplotype: Killer-cell Ig-like Receptor: Most common haplotype observed
    kir.2DL1*: Killer-cell Ig-like Receptor: 2DL1 observed; POS or NEG; and Copy number

    *Example description for the 2DL1 locus - results are available for 2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3, 3DS1, 2DP1, and 3DP1 loci.

    FCGR genotyping columns

    subject.subjectGuid: A Globally Unique Identifier (GUID) for the Subject
    sample.sampleKitGuid: A GUID for the Sample Kit, representing all material collected at a visit
    specimen.specimenGuid: A GUID for the specific aliquot used for the experiment
    fcgr.locus: FCGR: locus assesed; FCGR2A H131R or FCGR3A V158F
    fcgr.allele_1_g: FCGR: SNP nucleotide on allele 1
    fcgr_allele_2_g: FCGR: SNP nucleotide on allele 2
    fcgr.allele_1_a: FCGR: Amino acid generated by allele 1
    fcgr.allele_2_a: FCGR: Amino acid generated by allele 2

    NDMM Genotyping Results
    File NameDescriptionDownload Link
    ndmm_fcgr_genotyping.tsv FCGR genotyping results
    ndmm_fcgr_genotyping_desc.tsv FCGR genotyping result column descriptors
    ndmm_hla_genotyping.tsv HLA genotyping results
    ndmm_hla_genotyping_desc.tsv HLA genotyping result column descriptors
    ndmm_kir_genotyping.tsv KIR genotyping results
    ndmm_kir_genotyping_desc.tsv KIR genotyping result column descriptors

    Induction and Maintenance Administration

    Subjects in our study was treated with VRd, VRd with daratumumab, or other similar treatment courses as induction therapy, as well as post-transplant maintenance therapy. The timing, drugs, dosing, and administration details are provided in the tables below.

    Click the header below for descriptions of these treatment data:

    Induction therapy columns

    subject.subjectGuid: A Globally Unique Identifier (GUID) for the Subject
    treatment.cycleDaysSinceFirstVisit: Start of the treatment cycle as number of days after the first visit
    treatment.cycleNumber: Treatment cycle iteration number
    treatment.drugName: Drug administered as part of treatment
    treatment.drugDose: Dose of drug administered
    treatment.drugFrequency: Frequency of drug administration within cycle; D, days administered; Q, length of treatment cycle
    treatment.drugRoute: Route of drug administration; PO, per os (by mouth); subQ, subcutaneous injection; IV, intravenous injection

    Maintenance therapy columns

    subject.subjectGuid: A Globally Unique Identifier (GUID) for the Subject
    maintenance.iteration: Number of maintenance therapy treatment regimens administered to the subject
    maintenance.startDaysSinceFirstVisit: Day of start of maintenance therapy as days after the first visit
    maintenance.drugName: Drug administered as part of treatment
    maintenance.drugDose: Dose of drug administered
    maintenance.drugFrequency: Frequency of drug administration within cycle; D, days administered; Q, length of treatment cycle
    maintenance.numberOfCycles: Total number of cycles of administration of maintenance therapy
    maintenance.ongoing: Whether maintenance therapy was still administered at the end of data collection; Yes or No
    maintenance.endReason: Reason for end of maintenance therapy, if available
    maintenance.endDaysSinceFirstVisit: End of maintenance therapy as number of days after the first visit

    NDMM Therapy Administration Data
    File NameDescriptionDownload Link
    ndmm_induction_therapy.tsv Induction therapy administration data
    ndmm_induction_therapy_desc.tsv Induction therapy column descriptors
    ndmm_maintenance_therapy.tsv Maintenance therapy administration data
    ndmm_maintenance_therapy_desc.tsv Maintenance therapy column descriptors

    Standard Clinical Measures

    At clinical visits at which subjects contributed blood samples, we also collected samples for a battery of clinical laboratory tests including Blood Chemistry, Blood Counts, Cytogenetics results, Tumor Burden measures, and Lipid Profiles. These clinical laboratory results are available to download below.

    Descriptors of the columns in our clinical lab results table can be found in the downloadable "clinical_lab_descriptors" table, or by clicking the header below:

    Subject and Sample Metadata

    Our clinical labs dataset results contain some sample-level metadata to enable connection between these results and samples used in other modalities. The sample.sampleKitGuid identifier is used across many data modalities:

    Sample Identifiers
    cohort.cohortGuid: A Globally Unique Identifier (GUID) of the Cohort the subject enrolled in for our study
    subject.subjectGuid: A GUID for the Subject
    sample.sampleKitGuid: A GUID for the Sample Kit, representing all material collected at a visit

    Subject Metadata (prefix: subject)
    subject.treatmentGroup: Treatment group (VRd or VRd_dara)
    subject.biologicalSex: The biological sex of the Subject
    subject.race: The self-reported Race of the Subject
    subject.ethnicity: The self-reported Ethnicity of the subject

    Sample Metadata (prefix: sample)
    sample.visitName: The name of the study visit (i.e. time point)
    sample.visitDetails: Additional visit purpose/details, where available
    sample.daysSinceFirstVisit: Timing of the sample collection relative to the first visit date (usually Flu Year 1 Day 0)

    Clinical Lab Results

    Data in the following columns of our table are results from clinical laboratory tests. Below, we show the column name, full name, units used, and normal ranges (where available). Normal ranges are provided as a guide, but may vary between clinical laboratories.

    Blood counts (prefix: bc)

    bc.perc_basophils: % Basophils
    bc.perc_eosinophils: % Eosinophils
    bc.perc_immature_granulocytes: % Immature Granulocytes
    bc.perc_lymphocytes: % Lymphocytes
    bc.perc_monocytes: % Monocytes
    bc.perc_neutrophils: % Neutrophils
    bc.basophil_count: Absolute Basophil Count (count per uL; 0-202)
    bc.eosinophil_count: Absolute Eosinophil Count (AEC) (count per uL; 0-400)
    bc.immature_granulocyte_count: Absolute Immature Granulocyte Count (count per uL; 0-500)
    bc.lymphocyte_count: Absolute Lymphocyte Count (ALC) (count per uL; 1000-4800)
    bc.monocyte_count: Absolute Monocyte Count (AMC) (count per uL; 200-900)
    bc.neutrophil_count: Absolute Neutrophil Count (ANC) (count per uL; 1800-6600)
    bc.hematocrit: Hematocrit (percent; 39.2-50.2)
    bc.hemoglobin: Hemoglobin (g per dL; 12.1-18.1)
    bc.mch: Mean Corpuscular Hemoglobin (MCH) (pg; 27.5-35.1)
    bc.mchc: Mean Corpuscular Hemoglobin Concentration (MCHC) (g per dL; 32-36)
    bc.mcv: Mean Corpuscular Volume (MCV) (fL; 80-100)
    bc.platelet_count: Platelet Count (thousand count per uL; 150-400)
    bc.red_blood_cell_count: Red Blood Cell Count (million count per uL; 4.18-6.09)
    bc.wbc: White Blood Cell Count (WBC) (thousand count per uL; 4-11.1)

    Tumor burden (prefix: tb)

    tb.riss_stage: RISS Stage
    tb.perc_abnormal_morph: % abnormal plasma cells by bone marrow morphology
    tb.perc_abnormal_flow: % abnormal plasma cells by flow cytometry
    tb.was_perc_abnormal_by_ihc: Was % abnormal plasma cells value determined by IHC (CD138+)?
    tb.end_induction_response: Investigator assessed response category at End of Induction Visit
    tb.post_trans_90d_response: Investigator assessed response category at 90 days Post-Transplant Visit
    tb.post_trans_1y_response: Investigator assessed response category at 1 year Post-Transplant Visit
    tb.post_trans_2y_response: Investigator assessed response category at 1 years Post-Transplant Visit

    Cytogenetics (prefix: cyto)

    cyto.17p_loss: Loss of chr17p; 17p-
    cyto.1p_loss: Loss of chr1p; 1p-
    cyto.1q_gain: Gain of crh1q; 1q+
    cyto.high_risk: High risk cytogenetics? (17p- t(4;14))
    cyto.karyotype: Whether karyotype was annotated as abnormal
    cyto.t11_14: Translocation of parts of chr11 and chr14; t(11:14)
    cyto.t14_16: Translocation of parts of chr14 and chr16; t(14:16)
    cyto.t14_20: Translocation of parts of chr14 and chr20; t(14:20)
    cyto.t4_14: Translocation of parts of chr4 and chr14; t(4:14)

    Blood chemistry (prefix: chem)

    chem.alt: Alanine Transaminase (ALT) (Units per L; 7-52)
    chem.albumin: Albumin (g per dL; 3.5-5.7)
    chem.alkaline_phosphatase: Alkaline Phosphatase (Units per L; 39-117)
    chem.anion_gap: Anion Gap (mmol per L; 4-16)
    chem.ast: Aspartate Aminotransferase (AST) (Units per L; 12-39)
    chem.t_bili: Bilirubin, Total (T-Bili) (mg per dL; 0.1-1.3)
    chem.bun: Blood Urea Nitrogen (BUN) (mg per dL; 7-25)
    chem.calcium: Calcium (mg per dL; 8.6-10.3)
    chem.co2: Carbon Dioxide (CO2) (mmol per L; 21-31)
    chem.cl: Chloride (Cl) (mmol per L; 98-108)
    chem.creatinine: Creatinine (mg per dL; 0.7-1.3)
    chem.glucose: Glucose (mg per dL; 70-199)
    chem.ldh: Lactate Dehydrogenase (Units; 0-210)
    chem.magnesium: Magnesium (mg per dL; 1.8-2.4)
    chem.phosphate: Phosphate (mg per dL; 2.5-4.5)
    chem.potassium: Potassium (mmol per L; 3.5-5.1)
    chem.protein: Protein, Total (g per dL; 6.4-8.9)
    chem.sodium: Sodium (mmol per L; 133-145)

    CMV serology (prefix: cmv)

    cmv.ab_visit: CMV Ab Screen Visit Name
    cmv.ab_screen_index_value: CMV Ab Screen Index Value
    cmv.ab_screen_result: CMV Ab Screen Result

    Serum protein electrophoresis (prefix: spe)

    spe.albumin: Albumin (Serum Protein Electrophoresis) (g per dL; 3.5-4.9)
    spe.alpha1: Alpha 1 (Serum Protein Electrophoresis) (g per dL; 0.1-0.3)
    spe.alpha2: Alpha 2 (Serum Protein Electrophoresis) (g per dL; 0.3-0.8)
    spe.beta: Beta (Serum Protein Electrophoresis) (g per dL; 0.6-1)
    spe.b2m: Beta 2 Microglobulin (μg per mL; 0-2.5)
    spe.gamma: Gamma (Serum Protein Electrophoresis) (g per dL; 0.4-1.4)
    spe.protein: Protein, Total (Serum Protein Electrophoresis) (g per dL; 6-8.2)

    Inflammation assays (prefix: infl)

    infl.hs_crp: C-Reactive Protein, High-Sensitivity (HS-CRP) (mg per L; 0-0.3)
    infl.esr: SED Rate-Westergren (ESR) (mm per hour; 0-20)

    Lipid panel (prefix: lip)

    lip.cholesterol_hdl: Cholesterol, HDL (mg per dL; 40-59)
    lip.cholesterol_ldl: Cholesterol, LDL (mg per dL; 57-129)
    lip.cholesterol_non_hdl: Cholesterol, Non-HDL (mg per dL; 0-189)
    lip.cholesterol_total: Cholesterol, Total (mg per dL; 136-239)
    lip.cholesterol_hdl_ratio: Cholesterol/HDL Ratio
    lip.triglycerides: Triglycerides (mg per dL; 48-149)

    Immunoglobulin measurements (prefix: ig)

    ig.immunofixation: Immunofixation
    ig.iga: Immunoglobulin A (mg per dL; 84-499)
    ig.igg: Immunoglobulin G (mg per dL; 610-1616)
    ig.igm: Immunoglobulin M (mg per dL; 40-350)
    ig.k_flc: Kappa Free Light Chain (mg per dL; 0.33-1.94)
    ig.kl_flc_ratio: Kappa/Lambda FLC Ratio
    ig.l_flc: Lambda Free light chain (mg per dL; 0.57-2.63)
    ig.mono_1_id: Monoclonal 1 ID, Serum
    ig.mono_1_quant: Monoclonal 1 Quantification, Serum (g per dL)

    NDMM Clinical Labs and Metadata
    File NameDescriptionDownload Link
    ndmm_clinical_labs_and_metadata.tsv Clinical labs and metadata table
    ndmm_clinical_labs_and_metadata_desc.tsv Column descriptors for clinical labs and metadata